Amalgamated Bank’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Amalgamated Bank’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,951	Closed	-$7K	–	3212
2023 Q1	$7K	Sell	3,951 -976	-20%	-$1.21K	﹤0.01%	2873
2022 Q4	$5K	Hold	4,927	–	–	﹤0.01%	2945
2022 Q3	$12K	Hold	4,927	–	–	﹤0.01%	2922
2022 Q2	$15K	Buy	4,927 +941	+24%	+$4.58K	﹤0.01%	2926
2022 Q1	$27K	Buy	+3,986	New	+$28.4K	﹤0.01%	2713

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Amalgamated Bank's JNCE Position: Q2 2023 in Review

Amalgamated Bank sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 3,951 shares — an estimated $7K sold.

Amalgamated Bank first reported a position in JNCE in Q1 2022 and held it in 5 quarters. The position peaked at $27K in Q1 2022. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Amalgamated Bank reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Amalgamated Bank sold 3,951 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $7K.
Amalgamated Bank first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Amalgamated Bank's Jounce Therapeutics, Inc. Common Stock position peaked at $27K in Q1 2022.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Amalgamated Bank's 13F filing for Q2 2023, filed 11 Aug 2023.